We are live on ! Find out more
PRME icon

Prime Medicine
PRME

79 hedge funds and large institutions have $676M invested in Prime Medicine in 2023 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 36 increasing their positions, 13 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

177% more repeat investments, than reductions

Existing positions increased: 36 | Existing positions reduced: 13

32% more capital invested

Capital invested by funds: $512M → $676M (+$164M)

23% more first-time investments, than exits

New positions opened: 16 | Existing positions closed: 13

4.53% more ownership

Funds ownership: 42.92% → 47.45% (+4.5%)

4% more funds holding

Funds holding: 76 → 79 (+3)

33% less funds holding in top 10

Funds holding in top 10: 3 → 2 (-1)

Holders
79
Holders Change
+3
Holders Change %
+3.95%
% of All Funds
1.24%
Holding in Top 10
2
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-33.33%
% of All Funds
0.03%
New
16
Increased
36
Reduced
13
Closed
13
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$34.2M
2
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group
Japan
+$28.8M
3
NAMA
Nikko Asset Management Americas
New York
+$28.8M
4
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$20M
5
BlackRock
BlackRock
New York
+$19.2M

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$62.5M
2
AI
Alphabet Inc
California
-$19.9M
3
RG
Redmile Group
California
-$9.33M
4
CAM
Cormorant Asset Management
Massachusetts
-$9.03M
5
CC
Casdin Capital
New York
-$5.13M
Name Holding Trade Value Shares
Change 		Change in
Stake
Bank of America
26
Bank of America
North Carolina
$2.16M -$38.4K -2,752 -2%
Charles Schwab
27
Charles Schwab
California
$2.07M +$945K +67,717 +92%
N
28
Nuveen
North Carolina
$1.8M +$1.52M +109,067 +772%
Bank of New York Mellon
29
Bank of New York Mellon
New York
$1.51M +$1.02M +73,145 +243%
UBS Group
30
UBS Group
Switzerland
$1.45M +$1.31M +94,104 +1,907%
TD Asset Management
31
TD Asset Management
Ontario, Canada
$983K +$602K +43,149 +180%
Manulife (Manufacturers Life Insurance)
32
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$856K +$178K +12,770 +28%
Morgan Stanley
33
Morgan Stanley
New York
$849K +$343K +24,544 +74%
LCM
34
Laurion Capital Management
New York
$819K -$57.4K -4,112 -7%
RhumbLine Advisers
35
RhumbLine Advisers
Massachusetts
$689K +$657K +47,063 New
BM
36
Brandywine Managers
Delaware
$483K – – –
JP Morgan Chase
37
JP Morgan Chase
New York
$449K +$248K +17,775 +138%
AllianceBernstein
38
AllianceBernstein
Tennessee
$389K +$371K +26,540 New
MIM
39
MetLife Investment Management
New Jersey
$311K +$212K +15,171 +249%
HighTower Advisors
40
HighTower Advisors
Illinois
$310K +$298K +21,322 New
LCS
41
Levin Capital Strategies
New York
$293K +$279K +20,000 New
AIG
42
American International Group
New York
$279K +$195K +13,953 +274%
Mirae Asset Global Investments
43
Mirae Asset Global Investments
South Korea
$276K +$263K +18,871 New
Principal Financial Group
44
Principal Financial Group
Iowa
$264K +$252K +18,029 New
Deutsche Bank
45
Deutsche Bank
Germany
$261K +$97.1K +6,952 +64%
Wells Fargo
46
Wells Fargo
California
$239K +$200K +14,361 +742%
CGL
47
Clarius Group LLC
Washington
$236K – – –
New York State Common Retirement Fund
48
New York State Common Retirement Fund
New York
$234K +$114K +8,191 +105%
VOYA Investment Management
49
VOYA Investment Management
Georgia
$231K +$220K +15,743 New
OC
50
Oppenheimer & Co
New York
$225K +$3.73K +267 +2%
1
2
3 4

PRME Hedge Fund Activity: Q2 2023 in Review

79 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Prime Medicine (PRME) for Q2 2023, worth a combined $676M — up 32% from $512M a quarter earlier.

Buyers outnumbered sellers: 16 funds opened new PRME positions and 13 closed out — a net gain of 3 holders — while 36 added to existing stakes and 13 trimmed.

The largest buyer was Vanguard Group, adding an estimated $34.2M. The largest seller was Fidelity Investments, cutting an estimated $62.5M.

  • 79 institutional investors held Prime Medicine (PRME) as of Q2 2023, up from 76 in Q1 2023.
  • Funds reported $676M of Prime Medicine stock for Q2 2023, up 32% quarter-over-quarter.
  • 16 funds opened new Prime Medicine positions in Q2 2023 and 13 closed out, a net change of +3 holders.
  • The largest Prime Medicine buyer in Q2 2023 was Vanguard Group, an estimated $34.2M added.
  • The largest Prime Medicine seller in Q2 2023 was Fidelity Investments, an estimated $62.5M sold.

Based on aggregated 13F filings for Q2 2023.